Steady-state pharmacokinetics of plasma tenofovir alafenamide (TAF), tenofovir (TFV) and emtricitabine (FTC), and intracellular TFV-diphosphate and FTC-triphosphate in HIV-1 infected old Japanese patients treated with bictegravir/FTC/TAF-Reference-Cited by-同舟云学术

Steady-state pharmacokinetics of plasma tenofovir alafenamide (TAF), tenofovir (TFV) and emtricitabine (FTC), and intracellular TFV-diphosphate and FTC-triphosphate in HIV-1 infected old Japanese patients treated with bictegravir/FTC/TAF

Published:2023-08-31 Issue:4 Volume:5 Page:216-222
ISSN:2434-9186
Container-title:Global Health & Medicine
language:en
Short-container-title:GHM

Author:

Tran Trung Hieu¹,Tsuchiya Kiyoto¹,Kawashima Akira²,Watanabe Koji¹,Hayashi Yoshiharu³,Ryu Shoraku³,Hamada Akinobu³,Gatanaga Hiroyuki¹,Oka Shinichi¹

Affiliation:

1. AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.

2. The Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.

3. Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.

Publisher

National Center for Global Health and Medicine (JST)

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/ghm/5/4/5_2023.01060/_pdf

Reference22 articles.

1. 1. Pharmacoeconomic Review Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) (Biktarvy): (Gilead Sciences Canada, Inc.): Indication: A complete regimen for the treatment of HIV-1 infection in adults with no known substitution associated with resistance the individual components of Biktarvy. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018. http://www.ncbi.nlm.nih.gov/books/NBK539546/ (accessed May 8, 2023)

2. 2. Gilead. Biktarvy, Bictegravir/Emtricitabine/Tenofovir Alafenamide: EU SUMMARY OF PRODUCT CHARACTERISTICS. 2018. https://www.ema.europa.eu/en/documents/product-information/biktarvy-epar-product-information_en.pdf (accessed May 8, 2023)

3. 3. Kawashima A, Trung HT, Watanabe K, Takano M, Deguchi Y, Kinoshita M, Uemura H, Yanagawa Y, Gatanaga H, Kikuchi Y, Oka S, Tsuchiya K. Pharmacokinetics of bictegravir in older Japanese people living with HIV-1. Microbiol Spectr. 2023; 11:e0507922.

4. 4. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018; 320:379-396.

5. 5. European AIDS Clinical Society (EASC). Guidelines version 10.1. 2020. https://www.eacsociety.org/media/guidelines-10.1_30032021_1.pdf (accessed May 8, 2023)

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence;Journal of Infection and Chemotherapy;2024-09

2. Profiling the Interaction between Human Serum Albumin and Clinically Relevant HIV Reverse Transcriptase Inhibitors;Viruses;2024-03-22